Status:
COMPLETED
Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)
Lead Sponsor:
Arbeitsgemeinschaft medikamentoese Tumortherapie
Collaborating Sponsors:
Mundipharma Pte Ltd.
Conditions:
Leukemia, Lymphocytic, Chronic, B-Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The primary objective of this study is to determine the percentage of patients achieving a response, defined as the percentage of patients achieving complete response, partial response and stable dise...
Detailed Description
This is a non-randomized, multicenter, open-label, single-arm Phase I/II study to evaluate the safety and efficacy of bendamustine combined with alemtuzumab in patients with pretreated CD20-positive C...
Eligibility Criteria
Inclusion
- Male or female patients with CD23+, CD5+, CD19+ light chain monoclonal B-CLL with treatment indication according to IWCLL criteria (Appendix 4)
- 1st or greater relapse after fludarabine or any other primary treatment regimen OR Refractory to any previous treatment and simultaneous indication for treatment according to IWCLL criteria (Appendix 4)
- Age 18 years and older
- ECOG status 0 - 2
- Life expectancy \> 6 months
- Written informed consent given by the patient
- Patient using a reliable means of contraception (e.g. physical barrier, contraceptive pill or patch, spermicide and barrier, or IUD) for the duration of the study. Male patients have to use an adequate contraception method for the duration of study treatment and for 6 months following completion of study treatment. Women of childbearing potential have to use an effective method of contraception for the duration of study participation.
Exclusion
- HIV positive or positive for Hepatitis B or C
- Active uncontrolled infection
- Pregnant or lactating women
- Hypersensitivity with anaphylactic reaction to humanised monoclonal antibodies or to the excipients of any of the applied drugs (e.g. Bendamustine hydrochloride or mannitol)
- Previous treatment with bendamustine
- Treatment with an experimental drug within the previous 2 months
- Patients with a history of other malignancies within 2 years prior to study entry, except for adequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low grade, early stage localized prostate cancer treated surgically with curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with curative intent.
- Transformation to aggressive B-cell malignancy (e.g. large B-cell lymphoma, Richter's syndrome, or prolymphocytic leukemia (PLL)
- Decreased kidney function with creatinine clearance \< 30 ml/min
- Patients with severe co-morbidities or major organ dysfunctions (e.g. known severe liver damage, jaundice)
- Patients with a history of severe cardiac disease; e.g. NYHA Functional Class III or IV heart failure, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, or unstable angina
- Any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent, or patients unable to comply with requirements of study protocol
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 6 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00951457
Start Date
March 1 2009
End Date
August 6 2012
Last Update
March 3 2022
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie
Innsbruck, Tyrol, Austria, A-6020
2
Landeskrankenhaus Feldkirch
Feldkirch, Austria, A-6806
3
A.ö. Landeskrankenhaus Leoben
Leoben, Austria, A-8700
4
Krankenhaus der Elisabethinen Linz
Linz, Austria, A-4010